From heparin to EP217609: The long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile

Summary

The elucidation of the structure of the antithrombin binding sequence in heparin has given a large impulse to the rational design of heparin related drugs. De novo chemical synthesis of the corresponding pentasaccharide as well as simplified analogues has provided very specific, antithrombin-mediated inhibitors of factor Xa with various pharmacokinetic profiles. Fondaparinux and idraparinux are examples of such compounds that have found clinical application as antithrombotics. Because of the very specific binding to antithrombin the pharmacokinetics of pentasaccharides can be predicted and transferred to other molecules covalently bound to them. The new chemical entities thus obtained display a wide array of antithrombotic activities, giving improved heparin molecules as well as new anticoagulants, devoid of the undesired side effects of heparin and with unprecedented pharmacological profiles. In this context, a direct thrombin inhibitor was covalently coupled to a pentasaccharide by an inert spacer.This compound, EP42675 exerts antithrombin mediated anti-factor Xa activity together with direct thrombin inhibiting capacity. It displays favourable pharmacokinetics as imposed by the pentasaccharide. EP42675 was further modified by the introduction of a biotin moiety in its structure.The new entity obtained, EP217609 exerts the same pharmacological profile as EP42675 and it can be instantaneously neutralised by injection of avidin. Due to this unprecedented mechanism of anticoagulant activity and its ability to be neutralised,EP217609 deserves to be investigated in clinical settings where direct thrombin inhibition is required.

Keywords

Antithrombin - coagulation inhibitors - drug design - heparin - thrombosis

^* DM is a consultant for Endotis Pharma.

• References

• 1 Heparin. Chemical and Biological Properties - Clinical applications. Edward Arnold; London: 1989. 455.
• 2 Verstraete MJ, Chesebro JH, Fuster V. Antithrombotic therapy Atherosclerosis and Coronary Artery Disease. In : Lippincott-Raven: Philadelphia, Pa; 1995: 979-994.
• 3 Mark DB, Braunwald E. Medical management of unstable angina Atherosclerosis and Coronary Artery Disease. In : Lippincott-Raven: Philadelphia, Pa; 1995: 1315-1326.
• 4 Telford AM, Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndromes. Lancet 1981; 01: 1225-1228.
• 5 Theroux P, Ouimet H, McCains J. et al. Aspirin, heparin or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105-1111.
• 6 Dray E, Mulloy B, Barrowcliffe TW. Heparin and low-molecular-weight heparin. Thromb Haemost 2008; 99: 897-818.
• 7 Petitou M, Casu B, Lindahl U. 1976-1983, a critical period in the history of heparin: the discovery of the antithrombin binding site. Biochimie, 2003; 85: 83-89.
• 8 Rosenberg RD. Actions and interactions of antithrombin and heparin. New Eng J Med 1995; 292: 146-151.
• 9 Lane DA, MacGregor IR, Michalski R. et al. Anticoagulant activities of four unfractionated and fractionated heparins. Thromb Res 1978; 12: 257-271.
• 10 Oosta GM, Gardner WT, Beeler DL. et al. Multiple functional domains of the heparin molecule. Proc Natl Acad Sci USA 1981; 78: 829-833.
• 11 Lindahl U, Backstrom G, Hook M. et al. Structure of the antithrombin-binding site in heparin. Proc Natl Acad Sci USA 1979; 76: 3198-3202.
• 12 Choay J, Lormeau JC, Petitou M. et al. Low molecular weight oligosaccharides active in plasma against factor Xa. II New structural elements and antithrombotic activity. Ann Pharm Fr 1981; 39: 267-272.
• 13 Thunberg Bäckström G, Lindahl U. Further characterization of the antithrombin-binding sequence in heparin. Carbohydr Res 1982; 100: 393-410.
• 14 Lindahl U, Bäckström G, Thunberg L. et al. Evidence for 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin. Proc Natl Ac Sci USA 1980; 77: 6551-6555.
• 15 Lindahl U, Bäckström G, Thunberg L. The antithrombin binding sequence in heparin: identification of an essential 6-O-sulfate group. J Biol Chem 1983; 258: 9826-9830.
• 16 Riesenfeld J, Thunberg L, Höök M. et al. The antithrombinding-binding sequence of heparin. Location of essential N-sulfate groups. J Biol Chem 1981; 256: 2389-2394.
• 17 Choay J, Petitou M, Lormeau JC. et al. Structureactivity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high antifactor Xa activity. Biochem Biophys Res Commun 1983; 116: 492-499.
• 18 van Boeckel CAA, Beetz T, Vos JN. et al. Synthesis of a pentasaccharide corresponding to the antithrombin III binding fragment of heparin. J Carbohydr Chem 1985; 04: 293-321.
• 19 van Boeckel CAA, Petitou M. The unique antithrombin binding domain of heparin: A lead to new synthetic antithrombotics. Angew Chem Int Ed Engl 1993; 32: 1671-1690.
• 20 Petitou M, van Boeckel CAA. A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next?. Angew Chem Int Ed Engl 2004; 43: 3118-3133.
• 21 Meuleman DG, Hobbelen PMJ, van Dinther TG. et al. Antifactor Xa activity and antithrombotic activity in rats of structural analogues of the minimum antithrombin III binding sequence: Discovery of compounds with a longer duration of action than that of the natural pentasaccharide. Sem Thromb Haemost 1991; 17: 112-117.
• 22 Carrie D, Caranobe C, Saivin S. et al. Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to ATIII in the rabbit: comparison with CY216. Blood 1995; 84: 2571-2577.
• 23 van Amsterdam GMTVogel, Visser A. et al. Synthetic analogues of the antithrombin III-binding pentasaccharides sequence in heparin. Prediction of in vivo residence times. Arterioscler Thromb Vasc Biol 1995; 15: 495-503.
• 24 Herbert JM, Petitou M, Lormeau JC. et al. SR90107/ORG 31540, a novel anti-factor Xa antithrombotic agent. Cardiovascular Drug Reviews 1997; 15: 1-26.
• 25 Blick SK, Orman JS, Wagstaff AJ. et al. Fondaparinux sodium: a review of its use in the management of acute coronary syndromes. Am J Cardiovasc Drugs 2008; 08: 113-125.
• 26 Reynolds NA, Perry CM, Scott LJ. Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery. Drugs 2004; 64: 1575-1596.
• 27 Savi P, Herault JP, Duchaussoy P. et al. Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy. J Thromb Haemost 2008; 06: 1697-706.
• 28 Harenberg J, Jörg I, Vukojevic Y. et al. Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials. Eur J Clin Pharmacol 2008; 64: 555-63.
• 29 Herbert JM, Herault JP, Bernat A. et al. Biochemical and pharmacological properties of Sanorg 34006, a potent and long-acting synthetic pentasacharide Blood. 1998; 11: 4197-4205.
• 30 Prandoni P, Tormene D, Periati M. et al. Idraparinux: review of its clinical efficacy and safety for the prevention and treatment of thromboembolic disorders. Exp Opin Investig Drugs 2008; 17: 773-777.
• 31 Chong BH. Heparin-induced thrombocytopenia. J Thromb Haemost 2003; 01: 1471-1478.
• 32 Vogel GMT, van Amsterdam RGM, van Dinther TG. et al. Pre-clinical pharmacological profile of the novel glycoconjugate Org 36764 with both factor Xa and thrombin (IIa) inhibitory activities. Thromb Haemost 2000; 84: 611-620.
• 33 Herbert JM, Herault JP, Bernat A. et al. SR123781, a synthetic heparin mimetic. Thromb Haemost 2001; 85: 852-860.
• 34 de Kort M, Gianotten B, Wisse JA. et al. Conjugation of ATIII-binding pentasaccharides to extend the half-life of proteins: long-acting insulin. ChemMedChem 2008; 03: 1189-1193.
• 35 Becker RC, Spencer FA, Li Y. et al. Thrombin generation after abrupt cessation of intravenous unfractionated heparin amog patients with acute coronary syndromes ; Potential mechanisms for heightened prothrombotic potential. J Am Coll Cardiol 1999; 34: 1020-1027.
• 36 Antman E. The search for replacements for unfractionated heparin. Circulation 2001; 103: 2310-2323.
• 37 Buijsman RC, Basten JE, van Dinther TG. et al. Design and synthesis of a novel synthetic NAPAP-pentasaccharide conjugate displaying a dual antithrombotic action. Bioorg Med Chem Lett 1999; 09: 2013-2018.
• 38 De Kort M, Buijsman RC, van Boeckel CA. Synthetic heparin derivatives as new anticoagulant drugs Drug Discov Today. 2005; 10: 769-779.
• 39 Sturzebecher J, Vieweg H, Wikstrom P. et al. Interactions of thrombin with benzamidine-based inhibitors. Biol Chem Hoppe Seyler 1992; 373: 491-196.
• 40 Bates SM, Weitz JI. Emerging anticoagulant drugs. Arterioscler Thromb Vasc Biol 2003; 23: 1491-1500.
• 41 Vogel GMT, Meuleman DG, van Dinther TG. et al. Antithrombotic properties of a direct thrombin inhibitor with a prolonged half-life and AT-mediated factor Xa inhibitory activity. J Thromb Haemost 2003; 01: 1945-1954.
• 42 Savi P, Herault JP, Duchaussoy P. et al. Reversible biotinylated oligosaccharides: A new approach for a better management of anticoagulant therapy. J Thromb Haemost 2008; 06: 1697-706.
• 43 De Kort M, van Boeckel CAA. Patent WO2006067173, “Antithrombotic dual inhibitors comprising a biotin residue”, published 29 June. 2006